Non-Interventional Study to Investigate the Effectiveness, Safety and Utilization of Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions (NIELS)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Acronyms NIELS
- Sponsors Roche
- 02 Oct 2017 Planned End Date changed from 1 Mar 2019 to 31 Mar 2019.
- 02 Oct 2017 Planned primary completion date changed from 1 Mar 2019 to 31 Mar 2019.
- 02 Oct 2017 Status changed from recruiting to active, no longer recruiting.